Pseudomonas Aeruginosa Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Pseudomonas Aeruginosa Treatment Market Trends and the Market is Segmented by Treatment (Monotherapy and Combination Therapy), Route of Administration (Nasal, Oral, and Intravenous), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Pseudomonas Aeruginosa Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Pseudomonas Aeruginosa Infection Treatment Market Size

Pseudomonas Aeruginosa Infection Treatment Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 4.70 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Pseudomonas Aeruginosa Infection Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Pseudomonas Aeruginosa Infection Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Pseudomonas Aeruginosa Infection Treatment Market Analysis

The Pseudomonas Aeruginosa Infection Treatment Market is expected to register a CAGR of 4.7% during the forecast period.

The market expanded during COVID-19 because some of the patients who received COVID-19 therapy in hospitals and other healthcare institutions had pseudomonas aeruginosa infections as a result of the use of ventilators and other medical devices. According to the study published in Cell Reports in August 2021, it was found that Pseudomonas aeruginosa, a common coinfecting infection in COVID-19 patients, causes illness aggravation. Pseudomonas aeruginosa abundance increases with SARS-CoV-2 viral RNA load. Individuals infected with P. aeruginosa and suffering from COVID-19 pneumonia were given "oral ciprofloxacin" drug formulations. Thus, the studies demonstrated that COVID-19 had a favourable impact on the growth of the studied market. However, the COVID-19 infection cases have been subsidized currently, studied market is expected to project stable growth over the forecast period due to the rising burden of pseudomonas aeruginosa infection.

The major factors such as the increasing incidence of infections associated with it such as pneumonia, cystic fibrosis, and urinary tract infections, the increasing development of products, increasing antibacterial resistance, and growing R&D activities are driving the growth of the Pseudomonas aeruginosa infection market.

The prevalence of hospital-acquired infections has increased in recent years. According to an article published in the National Library of Medicine in August 2022, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 and 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. As a result of the increased burden of P. aeruginosa infection, the demand for its treatment is predicted to rise over the projection period, thereby boosting the growth of the studied market.

Furthermore, growing research and development activities on pseudomonas aeruginosa infection are expected to support market expansion over the forecast period. For instance, according to ClinicalTrials.gov updated in October 2022, a study titled "A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa" is under phase II trials and expected to be completed by 2024. Thus, such a study is expected to bring an advanced product for treating pseudomonas aeruginosa infection, thereby boosting the market's growth.

Various organic and inorganic strategies by the market players are likely to support the growth of the market. For instance, in April 2021, UK-based Phico Therapeutics secured an initial USD 5.3 million grant from CARB-X for developing intravenous-engineered bacteriophage drugs to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Thus, all the aforementioned factors, such as the growing prevalence of pseudomonas aeruginosa infection and rising drug development and discovery activities, are expected to propel the growth of the market over the forecast period. However, drug resistance ability of pseudomonas aeruginosa may restraint the market growth over the forecast period.

Pseudomonas Aeruginosa Infection Treatment Industry Overview

The pseudomonas aeruginosa infection treatment market is fragmented and consists of several players. The majority of the Pseudomonas aeruginosa infection treatment drugs and therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution systems have established their positions in the market. Some of the market players are Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc., Merck & Co Inc., AbbVie Inc. (Allergan)

Pseudomonas Aeruginosa Infection Treatment Market Leaders

  1. Teva Pharmaceutical Industries Ltd

  2. Johnson & Johnson

  3. Pfizer Inc

  4. Merck & Co Inc

  5. AbbVie Inc. (Allergan)

  6. *Disclaimer: Major Players sorted in no particular order
Pseudomonas Aeruginosa Infection Treatment Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Pseudomonas Aeruginosa Infection Treatment Market News

  • In December 2022, Clarametyx Biosciences has begun a Phase Ia clinical trial of CMTX-101, an immune-enabling antibody therapy, to treat community-acquired bacterial pneumonia.
  • In March 2022, The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a roughly USD 2.5 million grant to two University of Maryland School of Pharmacy (UMSOP) staff members to examine how infections caused by the bacteria Pseudomonas aeruginosa develop multidrug resistance.

Pseudomonas Aeruginosa Infection Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Hospital-acquired Infections
    • 4.2.2 Investment in Research and Drug Discovery for Pseudomonas Aeruginosa
  • 4.3 Market Restraints
    • 4.3.1 Drug Resistance Ability of Pseudomonas Aeruginosa
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Treatment
    • 5.1.1 Monotherapy
    • 5.1.2 Combination Therapy
  • 5.2 Route of Administration
    • 5.2.1 Nasal
    • 5.2.2 Oral
    • 5.2.3 Intravenous
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc. (Allergan PLC)
    • 6.1.2 Teva Pharmaceutical Industries Ltd
    • 6.1.3 Pfizer Inc.
    • 6.1.4 Lupin Pharmaceuticals Inc.
    • 6.1.5 AstraZeneca PLC
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Bristol Myers Squibb Company
    • 6.1.8 Johnson & Johnson
    • 6.1.9 Baxter International Inc.
    • 6.1.10 Neopharma
    • 6.1.11 CARB-X Company
    • 6.1.12 Sanofi SA
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Pseudomonas Aeruginosa Infection Treatment Industry Segmentation

As per the scope of the report, pseudomonas aeruginosa is a rod-shaped, encapsulated, Gram-negative bacteria that causes diseases in humans. It infects people with weakened immune systems causing 'blue-green pus bacteria' associated with hospital-acquired infections such as ventilator-associated pneumonia and sepsis. Pseudomonas aeruginosa infection treatment drugs inhibit the growth of Pseudomonas aeruginosa or completely eliminate the bacterium. The Pseudomonas Aeruginosa Infection Treatment Market is Segmented by Treatment (Monotherapy and Combination Therapy), Route of Administration (Nasal, Oral, and Intravenous), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for all the above segments.

Treatment Monotherapy
Combination Therapy
Route of Administration Nasal
Oral
Intravenous
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Pseudomonas Aeruginosa Infection Treatment Market Research FAQs

What is the current Pseudomonas Aeruginosa Infection Treatment Market size?

The Pseudomonas Aeruginosa Infection Treatment Market is projected to register a CAGR of 4.7% during the forecast period (2025-2030)

Who are the key players in Pseudomonas Aeruginosa Infection Treatment Market?

Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc, Merck & Co Inc and AbbVie Inc. (Allergan) are the major companies operating in the Pseudomonas Aeruginosa Infection Treatment Market.

Which is the fastest growing region in Pseudomonas Aeruginosa Infection Treatment Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Pseudomonas Aeruginosa Infection Treatment Market?

In 2025, the North America accounts for the largest market share in Pseudomonas Aeruginosa Infection Treatment Market.

What years does this Pseudomonas Aeruginosa Infection Treatment Market cover?

The report covers the Pseudomonas Aeruginosa Infection Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Pseudomonas Aeruginosa Infection Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Pseudomonas Aeruginosa Treatment Industry Report

Statistics for the 2025 Pseudomonas Aeruginosa Infection Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pseudomonas Aeruginosa Infection Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Pseudomonas Aeruginosa Treatment Market Report Snapshots